Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency

NCT ID: NCT02168686

Last Updated: 2023-10-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-11-28
• Study Completion Date: 2019-08-29

Brief Summary

The ADVANCE study is being conducted by Adverum Biotechnologies, Inc. as an open-label, multicenter, dose-escalation study in order to assess the safety and protein expression of ADVM-043 following a single intravenous or intrapleural administration.

Detailed Description

Alpha-1 Antitrypsin (A1AT) is a major inhibitor of serine proteases and plays an important role in the lung as an inhibitor of neutrophil elastase. A1AT deficiency is associated with decreases in plasma A1AT levels and is associated with an increased risk for developing asthma, emphysema/COPD, and bronchiectasis. Much of the lung damage is thought to be caused by proteolytic damage from neutrophil elastase and other proteases.

ADVM-043 is an investigational gene therapy product (serotype AAVrh.10 vector) expressing human A1AT that is intended to deliver a functional gene to the liver of patients with A1AT deficiency. Study ADVM-043-01 will study up to 4 dose levels in up to 20 patients and assess the hypothesis that a single administration of an AAV vector expressing the human M-type A1AT (i.e., ADVM-043) to patients with A1AT deficiency is safe and results in persistent therapeutic levels of A1AT in blood and alveolar epithelial lining fluid (epithelial lining fluid is only to be collected in subjects who are dosed intrapleurally). The primary endpoint is safety, and changes in plasma A1AT levels at multiple time points up to 52 weeks after dosing. A prophylactic tapering corticosteroid regimen will be used to protect against potential vector induced transaminitis. Subjects will be followed for up to 52 weeks after dosing. Safety and efficacy data from the IV cohorts will be considered when determining whether to proceed to intrapleural administration. After completion of this study, subjects will be asked to enroll in a Long Term Follow Up study.

Conditions

Alpha 1-Antitrypsin Deficiency

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part A: Dose 1

ADVM-043, at the lowest dose of three planned dose levels, of 8E13 total vg (equivalent to 1E12 vg/kg based on an 80-kg patient) administered IV

Group Type: EXPERIMENTAL

ADVM-043

Intervention Type: GENETIC

Gene transfer vector administration

Part A: Dose 2

ADVM-043 at the intermediate dose of three planned dose levels, of 4E14 total vg (equivalent to 5E12 vg/kg based on an 80-kg patient) administered IV

Group Type: EXPERIMENTAL

ADVM-043

Intervention Type: GENETIC

Gene transfer vector administration

Part A: Dose 3

ADVM-043 at the highest dose of three planned dose levels, of 1.2E15 total vg (equivalent to 1.5E13 vg/kg based on an 80-kg patient) administered IV

Group Type: EXPERIMENTAL

ADVM-043

Intervention Type: GENETIC

Gene transfer vector administration

Part A: Dose 4

ADVM-043 administered at a dose that will be determined

Group Type: EXPERIMENTAL

ADVM-043

Intervention Type: GENETIC

Gene transfer vector administration

Part B (optional): Intrapleural administration

ADVM-043 administered intrapleurally at a dose that will be determined

Group Type: EXPERIMENTAL

ADVM-043

Intervention Type: GENETIC

Gene transfer vector administration

Interventions

ADVM-043

Gene transfer vector administration

Intervention Type: GENETIC

Other Intervention Names

AAVrh.10halpha1AT; AAVrh.10hA1AT

Eligibility Criteria

Inclusion Criteria

• Capable of providing informed consent
• Alpha1AT genotype of ZZ or Z Null
• Males and females 18 years and older
• Ongoing treatment with A1AT augmentation is not required, however any subject receiving A1AT augmentation therapy must be willing to washout. Washout is defined as at least 8 weeks between last augmentation therapy and pre-treatment plasma A1AT level
• Willing to remain off PAT for at least 3 months following treatment
• Body mass index 18 to 35 kg/m2
• Fertile men and women of childbearing potential must agree to use barrier contraception for 3 months after treatment

Exclusion Criteria

• FEV1 <35 percent of predicted value at the Screening visit
• Receiving systemic corticosteroids or other immunosuppressive medications
• Immunodeficiency disease or evidence of active infection of any type, including human immunodeficiency virus
• Abnormal liver function tests
• Organ transplant recipient or awaiting transplantation
• Participation in another current or previous gene transfer study
• AAVrh.10 neutralizing antibody titer ≥ 1:5
• Female who is pregnant or lactating
• History of alcohol or drug abuse within the past 5 years
• Any history of allergies that may prohibit study-specific investigations
• Receiving an investigational medicinal product or participating in another investigational study within 3 months prior to consent
• Cigarette smoking, or any other tobacco use, e-cigarettes or other recreational inhalant within 1 year of the Screening Visit

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Adverum Biotechnologies, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Charlton Strange, MD

Role: PRINCIPAL_INVESTIGATOR

Medical University of South Carolina, Charleston, SC, USA

Friedrich Kueppers, MD

Role: PRINCIPAL_INVESTIGATOR

Temple University Hospital, Philadelphia, PA, USA

Mark Brantly, MD

Role: PRINCIPAL_INVESTIGATOR

University of Florida, Gainesville, FL, USA

Kyle Hogarth, MD

Role: PRINCIPAL_INVESTIGATOR

University of Chicago Medical Center, Chicago, IL, USA

Igor Barjakatarevic, MD

Role: PRINCIPAL_INVESTIGATOR

Ronald Reagan UCLA Medical Center, Santa Monica, CA, USA

Locations

University of Florida

Gainesville, Florida, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Countries

United States

References

Remih K, Amzou S, Strnad P. Alpha1-antitrypsin deficiency: New therapies on the horizon. Curr Opin Pharmacol. 2021 Aug;59:149-156. doi: 10.1016/j.coph.2021.06.001. Epub 2021 Jul 10.

Reference Type: DERIVED

PMID: 34256305 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

ADVM-043-01

Identifier Type: -

Identifier Source: org_study_id